Chinese vaccine and biologic products developer and manufacturer Shenzhen Kangtai Biological Products has announced the pricing for an initial public offering (IPO) of shares to raise ¥138.2m ($20.08m) in gross proceeds.

The IPO includes 42 million shares priced at ¥3.29 ($0.48) a share, which will be listed in the Shenzhen Stock Exchange.

Australian biopharmaceutical company Telix Pharmaceuticals and French biotechnology company Atlab Pharma SAS will manufacture clinical material and jointly execute a multi-centre Phase IIb trial for the treatment of men with metastatic prostate cancer, with and without end-stage chemotherapy.

The two companies have reached an agreement for the same and intend to conclude therapeutic product development for prostate cancer through the partnership.

German healthcare company Fresenius SE & Co. subsidiary Fresenius Finance Ireland has completed three private placements of unsecured notes in order to fund the acquisition of Quironsalud, and for general corporate purposes.

“US-based Braeburn Pharmaceuticals has announced an IPO to raise gross proceeds of $138.46m.”

Two of the placements included 1.5% and 0.87% unsecured notes due 2024 and 2022 respectively, for gross proceeds of €700m ($742.54m) each, while the third one included 3% unsecured notes due in 2032 for gross proceeds of €500m ($530.4m).

Invetech and Erytech Pharma have partnered to develop scalable automated manufacturing systems to enable the commercial-scale manufacture of products based on ERYCAPS, a proprietary technology platform owned by the latter.

Australian-based Invetech develops cGMP manufacturing solutions for cell and advanced therapies. Erytech Pharma is a biopharmaceutical company based in France.

US-based Braeburn Pharmaceuticals has announced an IPO to raise gross proceeds of $138.46m.

The offering includes 7.6 million shares of its common stock priced at a minimum of $18 a share. The maximum price is fixed at $21 a share, which will result in gross proceeds of $1.6m.

Underwriters have been granted a 30-day option to purchase an additional 1.1 million shares to cover over-allotments, if any.